TELA Bio Inc. logo

TELA Bio Inc.

TELA | NASDAQ
Chart Builder DCF Calculator
$1.31
+$0.01 (+0.77%)
Sep 22, 2026, 11:09 AM ET · Market open

Company Profile

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Key Executives

Name Position
Antony Koblish Co-founder, Chief Executive Officer & Director
Heather C. Getz CEO & Director
Paul Talmo Chief Technology Officer
D. Taylor Ocasio General Counsel & Corporate Secretary
Gregory A. Firestone Chief Business Officer
Howard N. Langstein Chief Medical Officer
Jeffrey Blizard President
Jennifer Lou Armstrong Senior Vice President of Human Resources
Jim Hagen Senior VP of Strategic Commercial Operations & Marketing
Megan Smeykal Vice President, Corporate Controller, Chief Accounting Officer & Principal Accounting Officer
Michael Leonard Senior Vice President of Technical Operations
Roberto E. Cuca CFO, Corporate Secretary & COO

Latest SEC Filings

Date Type Title
Sep 04, 2026 PRE 14A Filing
Aug 31, 2026 8-K Current Report
Aug 19, 2026 4 Filing
Aug 17, 2026 4 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 13, 2026 8-K/A [Amend] Current Report
Aug 11, 2026 S-8 Filing
Aug 11, 2026 10-Q Quarterly Report
Aug 11, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings
TELA Bio Inc.
TELA Bio Inc. logo
Country United States
IPO Date Nov 6, 2019
Industry Medical - Devices
Sector Healthcare
Employees 218
CEO Heather Getz

Contact Details

1 Great Valley Parkway Malvern, Pennsylvania 19355 United States

Stock Details

Ticker Symbol TELA
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001561921
CUSIP Number 872381108
ISIN Number US8723811084
SIC Code 3841

© 2026 bestshares.com. All rights reserved.